Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Nitrogen containing heteroaryl compounds
8623866 Nitrogen containing heteroaryl compounds
Patent Drawings:

Inventor: Bleicher, et al.
Date Issued: January 7, 2014
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Wilson; James O
Assistant Examiner: Jaisle; Cecilia M
Attorney Or Agent:
U.S. Class: 514/236.5; 514/252.11; 514/255.05; 514/256; 544/122; 544/295; 544/296; 544/322
Field Of Search: ;544/322; ;544/122; ;544/296; ;544/295; ;514/256; ;514/236.5; ;514/252.11; ;514/255.05
International Class: C07D 239/42; A61K 31/5355; A01N 43/54; A61K 31/497; C07D 403/14; A61P 25/18
U.S Patent Documents:
Foreign Patent Documents: 2000/66566; WO2005/012485; 2005/021500; 2007/061360; 2008/106692; 2009/026241; 2011/089132
Other References: Fujishige et al., "J. Biol. Chem." 274:18438-18445 (1999). cited by applicant.
Conti et al., "Prog. Nucleic Acid Res. Mol. Biol." 63:1-38 (1999). cited by applicant.
Siuciak et al., "Neuropharmacology" 51(2):374-385 (2006). cited by applicant.
Rodefer et al., "Eur. J. Neuroscience" 2:1070-1076 ( 2005). cited by applicant.
Vandenberg et al., "Expert Opinion on Therapeutic Targets" 5(4):507-518 ( 2001). cited by applicant.
Loughney et al., "Gene" 234(1):109-117 ( 1999). cited by applicant.
Graybiel, A. M., "Curr. Biol." 10:R509-R511 ( 2000). cited by applicant.
Siuciak et al., "Neuropharmacology" 51(2):386-396 ( 2006). cited by applicant.
Sharma et al., "Psychiatry" 174( SUPPL 28):44-51 ( 1999). cited by applicant.
Soderling et al., "Current Opinion Cell Biol." 12:174-179 ( 2000). cited by applicant.
Lewis et al., "Neuron" 28:325-333 ( 2000). cited by applicant.
Coskran et al., "J. Histochem. Cytochem." 54(11):1205-1213 ( 2006). cited by applicant.
Seeger et al., "Brain Research" 985:113-126 ( 2003). cited by applicant.
Sano, H., "J. Neurochem." 105:546-556 ( 2008). cited by applicant.
Manallack et al., "J. Med. Chem." 48(10):3449-3462 ( 2005). cited by applicant.
Soderling et al., "Proc. Natl. Acad. Sci. USA" 96(12):7071-7076 ( 1999). cited by applicant.
Fujishige et al., "Eur. J. Biochem." 266(3):1118-1127 ( 1999). cited by applicant.
Javitt et al., "Biol. Psychiatry" 45:668-679 ( 1999). cited by applicant.
Beavo et al., "Physiol. Review" 75:725-748 ( 1995). cited by applicant.
Nakazato et al., "Expert Opinion on Therapeutic Patents" 10(1):75-98 ( 2000). cited by applicant.
Mizutani et al., Bioorganic & Medicinal Chemistry Letters 18:6041-6045 ( 2008). cited by applicant.
Peng et al., Heterocycles 65(10):2321-2327 ( 2005). cited by applicant.
Budesinsky et al., Collection Czech. Chem. Commun. 45(2):539-547 ( 1980). cited by applicant.
Neilsen et al., J. Heterocyclic Chem. 24:1621-1628 ( 1987). cited by applicant.
Fawcett et al., PNAS 97(7):3702-3707 ( 2000). cited by applicant.
Hassaneen et al., Z. Naturforsch 59:1132-1136 ( 2004). cited by applicant.
(European Search Report for PCT/EP2011/059234 Sep. 12, 2011). cited by applicant.









Abstract: The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) ##STR00001## wherein A.sup.1, A.sup.2, ##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.
Claim: The invention claimed is:

1. A compound of formula (I) ##STR00423## wherein A.sup.1 is selected from the group consisting of CH and N; A.sup.2 is selected from the group consisting ofCR.sup.19 and N, provided that A.sup.1 and A.sup.2 are not N simultaneously; ##STR00424## is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 to 3 substituents independently selected from the group consisting oflower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, --C(O)--N(R.sup.8).sub.2, --N(R.sup.8)--C(O)-lower alkyl, cyano, halogen, R.sup.9 and amino, and wherein said lower alkyl is optionallysubstituted by oxo, --C(O)OH, lower alkoxy-C(O)-- or R.sup.7, and wherein said lower alkoxy is optionally substituted by hydroxyl, lower alkoxy or --C(O)--N(R.sup.8).sub.2, and wherein said amino is optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl and lower alkyl-C(O)--; R.sup.1 is lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, loweralkyl-C(O)--, --O-lower haloalkyl, cyano, halogen, R.sup.7 or amino, wherein said lower alkyl is optionally substituted by R.sup.7, and wherein said amino is optionally substituted by 1 or 2 substituents independently selected from the group consistingof lower alkyl and lower-alkoxy-lower-alkyl; R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl; R.sup.4 is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 to 3 substituents independently selectedfrom the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano and amino, and wherein said amino is optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl; R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl, lower alkoxy, lower haloalkyl, lower cyanoalkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl,cycloalkyl or heterocyclyl, wherein said lower alkyl is optionally substituted by oxo, R.sup.7 or --N(R.sup.8).sub.2, and wherein said lower haloalkyl is optionally substituted by hydroxyl, and wherein said cycloalkyl and said heterocyclyl are optionallysubstituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, acetyl, cyano, --C(O)-lower alkoxy and --N(R.sup.8).sub.2,or R.sup.5 and R.sup.6, together with the nitrogen atom to which they are attached, form a heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl and said spiro-heterocyclyl are optionally substituted by 1 to 3 substituents independently selectedfrom the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano, oxo and amino, and wherein said amino is optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl and lower-alkoxy-lower-alkyl; R.sup.7 is cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; R.sup.8 is independently selected from the group consisting of hydrogen, lower alkyl, lower hydroxyalkyl andlower-alkoxy-lower-alkyl; R.sup.9 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, said heterocyclyl, said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the groupconsisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; and R.sup.19 is hydrogen or tetrahydrofuran-2-yl; or a pharmaceutically acceptable salt thereof.

2. A compound of formula (I) ##STR00425## wherein A.sup.1 and A.sup.2 are independently selected from the group consisting of CH and N, provided that A.sup.1 and A.sup.2 are not N simultaneously; ##STR00426## is aryl or heteroaryl, whereinsaid aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl optionally substituted by oxo or R.sup.7, lower alkoxy, lower hydroxyalkyl, lower haloalkyl,lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, --C(O)--N(R.sup.8).sub.2, --N(R.sup.8)--C(O)-lower alkyl, cyano, halogen, R.sup.9 and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl, lowerhydroxyalkyl and lower-alkoxy-lower-alkyl; R.sup.1 is lower alkyl optionally substituted by R.sup.7, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano, halogen, R.sup.7 or amino optionally substitutedby 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl; R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl; R.sup.4 is heteroaryl optionally substituted by 1 to 3 substituentsindependently selected from the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano and amino optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl; R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl optionally substituted by oxo or R.sup.7, lower haloalkyl, lower cyanoalkyl, lower hydroxyalkyl,lower-alkoxy-lower-alkyl, cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lowerhydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, acetyl, cyano and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl, or R.sup.5 and R.sup.6, togetherwith the nitrogen atom to which they are attached, form a heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl and said spiro-heterocyclyl are optionally substituted by 1 to 3 substituents independently selected from the group consisting ofhydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano, oxo and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of loweralkyl, lower hydroxyalkyl and lower-alkoxy-lower-alkyl; R.sup.7 is cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of loweralkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; R.sup.8 is independently selected from the group consisting of hydrogen, lower alkyl, lower hydroxyalkyl and lower-alkoxy-lower-alkyl; and R.sup.9 is cycloalkyl,heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, said heterocyclyl, said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl, lower hydroxyalkyl,lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; or a pharmaceutically acceptable salt thereof.

3. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.2 and R.sup.3 are hydrogen.

4. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.4 is 3-fluoro-phenyl, 4-fluoro-phenyl, pyridin-3-yl, 5-fluoro-pyridin-3-yl, pyrimidin-5-yl or pyrazin-2-yl.

5. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein ##STR00427## is selected from the group consisting of: ##STR00428## wherein R.sup.10 is lower alkyl, lower-alkoxy-lower-alkyl, lower haloalkyl, aryl orheteroaryl, wherein said lower alkyl is optionally substituted by cycloalkyl; and R.sup.11 is lower alkyl, lower-alkoxy-lower-alkyl, lower haloalkyl, lower hydroxyalkyl or heterocyclyl, wherein said lower alkyl is optionally substituted by cycloalkyl orheterocyclyl.

6. The compound or a pharmaceutically acceptable salt thereof of claim 5, wherein R.sup.10 is methyl, ethyl, cyclopropylmethyl, 2-methoxy-ethyl, 2,2,2-trifluoro-ethyl, 3,3,3-trifluoro-propyl, phenyl or pyridin-2-yl; and R.sup.11 is methyl,ethyl, isopropyl, isobutyl, cyclopropylmethyl, oxetan-2-ylmethyl, tetrahydro-furan-2-ylmethyl, tetrahydro-furan-3-ylmethyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2,2,2-trifluoro-ethyl, 3,3,3-trifluoro-propyl or tetrahydro-furan-3-yl.

7. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.1 is halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, --C(O)-lower alkyl, --O-lower haloalkyl, cycloalkyl, heterocyclyl oramino, and wherein said heterocyclyl is optionally substituted by lower alkyl, and wherein said amino is substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl.

8. The compound or a pharmaceutically acceptable salt thereof of claim 7, wherein R.sup.1 is chloro, methyl, 1-hydroxy-ethyl, 1-hydroxy-1-methyl-ethyl, isopropyl, isobutyl, tert-butyl, methoxymethyl, methoxy, 2,2,2-trifluoro-ethoxy, acetyl,cyclopropyl, cyclobutyl, cyclohexyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, azetidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 4-methyl-piperazin-1-yl, ethyl-methyl-amino or 2-methoxy-ethylamino.

9. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxy, lower haloalkyl, lower-alkoxy-lower-alkyl, cycloalkyl orheterocyclyl, wherein said lower alkyl is optionally substituted by dimethylamino or heterocyclyl, and wherein said lower haloalkyl is optionally substituted by hydroxyl, and wherein said cycloalkyl is optionally substituted by hydroxyl, and wherein saidheterocyclyl is optionally substituted by lower alkyl or --C(O)-lower alkoxy, or R.sup.5 and R.sup.6, together with the nitrogen atom to which they are attached, form an azetidine, pyrrolidine, piperidine, morpholine, piperazine, isoxazolidine or2-oxa-6-aza-spiro[3.3]heptane ring, wherein each of said azetidine, pyrrolidine, piperidine, morpholine, piperazine, isoxazolidine or 2-oxa-6-aza-spiro[3.3]heptane ring is optionally substituted by 1 or 2 substituents independently selected from thegroup consisting of hydroxyl, halogen, lower alkyl, lower hydroxyalkyl, lower alkoxy, oxo and amino, and wherein said amino is substituted by 2 lower alkyl.

10. The compound or a pharmaceutically acceptable salt thereof of claim 9, wherein R.sup.5 and R.sup.6 are independently hydrogen, methyl, tetrahydrofuran-2-yl-methyl, ethyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-ethyl, 2-fluoro-ethyl,2-hydroxy-1,1-dimethyl-ethyl, 2,2-difluoro-ethyl, 2,2,2-trifluoro-ethyl, 2,2,2-trifluoro-1-methyl-ethyl, 2-dimethylamino-ethyl, propyl, isopropyl, 2,3-dihydroxy-propyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 3-hydroxy-2-methyl-propyl,3-hydroxy-2,2-dimethyl-propyl, 2,2-difluoro-propyl, 3,3,3-trifluoro-2-hydroxy-propyl, 2-methoxy-2-methyl-propyl, butyl, isobutyl, 3-hydroxy-3-methyl-butyl, methoxy, cyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxy-cyclopentyl, cyclohexyl, oxetan-3-yl,3-methyl-oxetan-3-yl, tetrahydro-furan-3-yl, tetrahydro-pyran-4-yl, 1-methyl-azetidin-3-yl, pyrrolidin-3-yl, 1-methyl-pyrrolidin-3-yl, 1-(tert-butoxycarbonyl)pyrrolidin-3-yl, 1-methyl-piperidin-3-yl or 1-methyl-piperidin-4-yl, or R.sup.5 and R.sup.6,together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl or spiro-heterocyclyl ring selected from the group consisting of azetidin-1-yl, 3-hydroxy-azetidin-1-yl, 3-fluoro-azetidin-1-yl,3,3-difluoro-azetidin-1-yl, pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-methoxy-pyrrolidin-1-yl, 2-hydroxymethyl-pyrrolidin-1-yl, 3-dimethylamino-pyrrolidin-1-yl, 2,5-dimethyl-pyrrolidin-1-yl, 2,2-dimethyl-pyrrolidin-1-yl,3,3-dimethyl-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, piperidin-1-yl, 2-methyl-piperidin-1-yl, isoxazolidin-2-yl, morpholin-4-yl, 3-oxo-piperazin-1-yl and 2-oxa-6-aza-spiro[3.3]heptan-6-yl.

11. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-dimethylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-dimethylcarbamoyl-1-(2-methoxy-ethyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [5-dimethylcarbamoyl-1-(2-methoxy-ethyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid[3-dimethylcarbamoyl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-methylcarbamoyl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-methylcarbamoyl-1-(3,3,3-trifluoro-propyl)-1H-pyrazol-4-yl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid[5-methylcarbamoyl-1-(3,3,3-trifluoro-propyl)-1H-pyrazol-4-yl]-amide, or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-(2-methoxy-ethyl)-5-methylcarbamoyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-cyclopropylmethyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid(1-cyclopropylmethyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-methyl-3-(morpholine-4-carbonyl)-1-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid[3-(cyclopropyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-methyl-3-(piperidine-1-carbonyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylicacid [3-(cyclohexyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-(2-methoxy-ethyl)-3-methylcarbamoyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-(cyclopentyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid[3-(isopropyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-methyl-3-(pyrrolidine-1-carbonyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-methylcarbamoyl-1-phenyl-1H-pyrazol-4-yl)-amide, 6-Methoxymethyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-(2-methoxy-ethyl)-5-methylcarbamoyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-N-[1-methyl-3-(2-methyl-pyrrolidine-1-carbonyl)-1H-pyrazol-- 4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, N-(3-Cyclohexylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-6-cyclopropyl-3-(pyrim- idin-5-ylamino)-pyridine-2-carboximidicacid, N-[3-(Azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl]-6-cyclopropyl-3-(py- rimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-(3-cyclopropylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-3-(pyri- midin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[3-(3,3-dimethyl-pyrrolidine-1-carbonyl)-1-methyl-1H-pyra- zol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, N-(3-Cyclobutylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-6-cyclopropyl-3-(pyrim- idin-5-ylamino)-pyridine-2-carboximidicacid, and N-(3-Cyclopentylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-6-cyclopropyl-3-(pyri- midin-5-ylamino)-pyridine-2-carboximidic acid, or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-N-[3-(2,5-dimethyl-pyrrolidine-1-carbonyl)-1-methyl-1H-pyra- zol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[3-(3,3-difluoro-pyrrolidine-1-carbonyl)-1-methyl-1H-pyra- zol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[3-(3-dimethylamino-pyrrolidine-1-carbonyl)-1-methyl-1H-p-yrazol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-{3-[(3-hydroxy-propyl)-methyl-carbamoyl]-1-methyl-1H-pyra- zol-4-yl}-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[3-(2-hydroxy-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-3- -(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-{3-[(2-hydroxy-ethyl)-methyl-carbamoyl]-1-methyl-1H-pyraz-ol-4-yl}-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[3-(2-methoxy-1-methyl-ethylcarbamoyl)-1-methyl-1H-pyrazo- l-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[3-(2,3-dihydroxy-propylcarbamoyl)-1-methyl-1H-pyrazol-4-- yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[3-(2-hydroxy-2-methyl-propylcarbamoyl)-1-methyl-1H-pyraz-ol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, and 6-Cyclopropyl-N-[3-(3-hydroxy-pyrrolidine-1-carbonyl)-1-methyl-1H-pyrazol- -4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-N-[3-(2-hydroxy-1-methyl-ethylcarbamoyl)-1-methyl-1H-pyrazo- l-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-{3-[(2,3-dihydroxy-propyl)-methyl-carbamoyl]-1-methyl-1H-- pyrazol-4-yl}-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[3-(5-hydroxy-3,6-dihydro-2H-pyrazine-1-carbonyl)-1-methy-l-1H-pyrazol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[3-(3-methoxy-pyrrolidine-1-carbonyl)-1-methyl-1H-pyrazol- -4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[3-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-1-methyl-1H-p- yrazol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[3-(3-hydroxy-azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4--yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[1-methyl-3-(2-oxa-6-aza-spiro[3.3]heptane-6-carbonyl)-1H- -pyrazol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[3-(2,2-dimethyl-pyrrolidine-1-carbonyl)-1-methyl-1H-pyra- zol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (4-methylcarbamoyl-[1,2,3]thiadiazol-5-yl)-amide,and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (4-methylcarbamoyl-2-phenyl-thiazol-5-yl)-amide, or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (4-methylcarbamoyl-2-pyridin-2-yl-thiazol-5-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-dimethylcarbamoyl-1-pyridin-2-yl-1H-pyrazol-4-yl)-amide, 2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,2-Cyclopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-tert-Butyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,2-Isobutyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-Cyclohexyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-cyclopropylcarbamoyl-thiophen-2-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-(morpholine-4-carbonyl)-thiophen-2-yl]-amide, and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [5-isopropyl-3-(morpholine-4-carbonyl)-thiophen-2-yl]-amide, or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1, selected from the group consisting of: 6-cyclopropyl-N-(3-(2-hydroxy-2-methylpropylcarbamoyl)-1-methyl-1H-pyrazo- l-4-yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide,N-(1-methyl-3-(methylcarbamoyl)-1H-pyrazol-4-yl)-3-(pyrimidin-5-ylamino)-- 6-(tetrahydrofuran-2-yl)pyrazine-2-carboxamide, N-(1-methyl-3-(methylcarbamoyl)-1H-pyrazol-4-yl)-3-(pyrimidin-5-ylamino)-- 6-(tetrahydro furan-3-yl)pyrazine-2-carboxamide,N-(1-methyl-3-(methylcarbamoyl)-1H-pyrazol-4-yl)-3-(pyrimidin-5-ylamino)-- 6-(tetrahydrofuran-2-yl)picolinamide, 6-isobutyl-N-(1-methyl-3-(methylcarbamoyl)-1H-pyrazol-4-yl)-3-(pyrimidin-- 5-ylamino)pyrazine-2-carboxamide,6-cyclopropyl-N-(1-ethyl-3-(methylcarbamoyl)-1H-pyrazol-4-yl)-3-(pyrimidi- n-5-ylamino)pyrazine-2-carboxamide, 6-cyclopropyl-N-(1-ethyl-3-((tetrahydrofuran-2-yl)methylcarbamoyl)-1H-pyr- azol-4-yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide,6-cyclopropyl-N-(1-methyl-3-((tetrahydrofuran-2-yl)methylcarbamoyl)-1H-py- razol-4-yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide, 6-cyclopropyl-N-(3-((2-hydroxy-2-methylpropyl)(methyl)carbamoyl)-1-methyl--1H-pyrazol-4-yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide, and N-(3-(2-hydroxy-2-methylpropylcarbamoyl)-1-methyl-1H-pyrazol-4-yl)-2-meth- yl-5-(pyrimidin-5-ylamino)pyrimidine-4-carboxamide, or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1, selected from the group consisting of: 6-(1-Hydroxy-ethyl)-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide,2-(2-Methoxy-ethylamino)-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 3-(Pyrimidin-5-ylamino)-6-(tetrahydro-furan-3-yl)-pyridine-2-carboxylic acid(1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-methyl-4-methylcarbamoyl-thiazol-5-yl)-amide, 6-Isopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-ethyl-5-(2-hydroxy-2-methyl-propylcarbamoyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(1-ethyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-isobutyl-1H-pyrazol-4-yl]-amide- , or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(oxetan-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(3-methyl-oxetan-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-isobutyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-isopropyl-1H-pyrazol-4-yl]-amid- e, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(1-isopropyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(3-hydroxy-3-methyl-butylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid [1-methyl-5-(tetrahydro-furan-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(3-hydroxy-2,2-dimethyl-propylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-ami- de,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(3,3-difluoro-azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[1-methyl-5-(2,2,2-trifluoro-ethylcarbamoyl)-1H-pyrazol-4-yl]-amide, or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2,2-difluoro-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(3,3,3-trifluoro-2-hydroxy-propylcarbamoyl)-1H-pyrazol-4-yl]-- amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[1-(2-methoxy-ethyl)-5-methylcarbamoyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-(3-hydroxy-2-methyl-propylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-carbamoyl-1-methyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-(2-methoxy-2-methyl-propylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amid- e,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {5-[(2-hydroxy-2-methyl-propyl)-methyl-carbamoyl]-1-methyl-1H-pyrazol-4-y- l}-amide, and 2-tert-Butyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(pyrrolidine-1-carbonyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-dimethylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,3-(Pyrimidin-5-ylamino)-6-(tetrahydro-furan-3-yl)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-5-(tetrahydro-furan-2-yl)-pyrazine-- 2-carboxylic acid [5-(2-fluoro-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(3-cyclopropylcarbamoyl-isoxazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(2,2,2-trifluoro-1-methyl-ethylcarbamoyl)-1H-pyrazol-4-yl]-am- ide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid [5-(2,2-difluoro-propylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, and 6-Chloro-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-isobutylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(piperidine-1-carbonyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-dimethylcarbamoyl-1-ethyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-ethyl-5-(morpholine-4-carbonyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-fluoro-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-(3,3,3-trifluoro-propyl)-1H-pyr- azol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-methylcarbamoyl-1-(3,3,3-trifluoro-propyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(3-fluoro-azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-(2,2,2-trifluoro-ethyl)-1H-pyra- zol-4-yl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-methylcarbamoyl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4-yl]-amide, or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(morpholine-4-carbonyl)-1-pyrazol-4-yl]-amide,6-Acetyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (3-ethylcarbamoyl-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-amide,2-Isopropyl-5-(pyridin-3-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-(1-Hydroxy-ethyl)-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,5-(3-Fluoro-phenylamino)-2-isopropyl-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Methoxymethyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,5-(5-Fluoro-pyridin-3-ylamino)-2-isopropyl-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 5-(4-Fluoro-phenylamino)-2-isopropyl-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, and2-Cyclobutyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-ethylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrazin-2-ylamino)-pyrazine-2-carboxylicacid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-ethyl-5-ethylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(1-ethyl-5-isobutylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(ethyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyridin-3-ylamino)-pyrazine-2-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-dipropylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-(butyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {5-[(2-hydroxy-ethyl)-methyl-carbamoyl]-1-methyl-1H-pyrazol-4-yl}-amide, and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(isopropyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-diethylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(methyl-propyl-carbamoyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid{5-[ethyl-(2-hydroxy-ethyl)-carbamoyl]-1-methyl-1H-pyrazol-4-yl}-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[methyl-(tetrahydro-pyran-4-yl)-carbamoyl]-1H-pyrazol-4-yl}-a- mide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrazol-4-yl}-am- ide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid{1-ethyl-5-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrazol-4-yl}-ami- de, 6-Cyclopropyl-3-(pyridin-3-ylamino)-pyrazine-2-carboxylic acid [5-(azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(2-methyl-piperidine-1-carbonyl)-1H-pyrazol-4-yl]-amide, 3-[(4-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}--2-methyl-2H-pyrazole-3-carbonyl)-amino]-pyrrolidine-1-carboxylic acid tert-butyl ester, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[methyl-(2,2,2-trifluoro-ethyl)-carbamoyl]-1H-pyrazol-4-yl}-a- mide, or apharmaceutically acceptable salt thereof.

26. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(cyclopropyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(2-methyl-pyrrolidine-1-carbonyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[1-methyl-5-(methyl-oxetan-3-yl-carbamoyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(1-methyl-piperidin-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(1-methyl-piperidin-4-ylcarbamoyl)-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-methylcarbamoyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrazol-4-yl]-amide- , 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-(tetrahydro-furan-2-ylmethyl)-1- H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {5-[(2-fluoro-ethyl)-methyl-carbamoyl]-1-methyl-1H-pyrazol-4-yl}-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid{1-methyl-5-[methyl-(1-methyl-pyrrolidin-3-yl)-carbamoyl]-1H-pyrazol-4-yl- }-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-methylcarbamoyl-1-(tetrahydro-furan-3-yl)-1H-pyrazol-4-yl]-amide, or a pharmaceutically acceptablesalt thereof.

27. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(pyrrolidin-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-{[(S)-1-(tetrahydro-furan-2-yl)methyl]-carbamoyl}-1H-pyrazol-- 4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(1-methyl-5-{[(R)-1-(tetrahydro-furan-2-yl)methyl]-carbamoyl}-1H-pyr- azol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[methyl-(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrazol-4- -yl}-amide,6-Methoxy-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-(2-hydroxy-ethyl)-5-methylcarbamoyl-1H-pyrazol-4-yl]-amide,3-(Pyrimidin-5-ylamino)-6-(R)-tetrahydro-furan-3-yl-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 3-(Pyrimidin-5-ylamino)-6-(S)-tetrahydro-furan-3-yl-pyrazine-2-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[(S)-(tetrahydro-furan-3-yl)carbamoyl]-1H-pyrazol-4-yl}-amide- , and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[(R)-(tetrahydro-furan-3-yl)carbamoyl]-1H-pyrazol-4-yl}-amide- , or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-methylcarbamoyl-1-oxetan-2-ylmethyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-oxetan-2-ylmethyl-1H-pyrazol-4-- yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-methylcarbamoyl-1-(tetrahydro-furan-3-ylmethyl)-1H-pyrazol-4-yl]-- amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-(tetrahydro-furan-3-ylmethyl)-1- H-pyrazol-4-yl]-amide,3-(Pyrimidin-5-ylamino)-6-pyrrolidin-1-yl-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Morpholin-4-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Azetidin-1-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-(Ethyl-methyl-amino)-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-dimethylamino-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, and 2-Cyclopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, or a pharmaceutically acceptable salt thereof.

29. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(1-methyl-azetidin-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide,2-Isobutyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 4-Methyl-5'-(pyrimidin-5-ylamino)-3,4,5,6-tetrahydro-2H-[1,2]bipyrazinyl-- 6'-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(methoxy-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-(isoxazolidine-2-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-cyclopentylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide,5-(Pyrimidin-5-ylamino)-2-(2,2,2-trifluoro-ethoxy)-pyrimidine-4-carboxyli- c acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 3-(Pyrimidin-5-ylamino)-6-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid(1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-(1-Hydroxy-1-methyl-ethyl)-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxy- lic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, and6-(1-Hydroxy-1-methyl-ethyl)-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxyli- c acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [1-(2-methoxy-ethyl)-5-methylcarbamoyl-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-N-[3-(2-hydroxy-2-methyl-propylcarbamoyl)-1-methyl-1H-pyraz- ol-4-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,2-Isobutyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-(morpholine-4-carbonyl)-thiophen-2-yl]-amide,6-cyclopropyl-N-(3-(2-hydroxy-2-methylpropylcarbamoyl)-1-methyl-1H-pyrazo- l-4-yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide, 6-isobutyl-N-(1-methyl-3-(methylcarbamoyl)-1H-pyrazol-4-yl)-3-(pyrimidin-- 5-ylamino)pyrazine-2-carboxamide, and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide or a pharmaceutically acceptable salt thereof.

31. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2-hydroxy-2-methyl-propylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide,6-Isopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(3-methyl-oxetan-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(2,2-difluoro-ethylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 2-tert-Butyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide, 3-(Pyrimidin-5-ylamino)-6-(tetrahydro-furan-3-yl)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-Isopropyl-5-(pyridin-3-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, and5-(5-Fluoro-pyridin-3-ylamino)-2-isopropyl-pyrimidine-4-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide or a pharmaceutically acceptable salt thereof.

32. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-ethylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid [5-(ethyl-methyl-carbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, 3-(Pyrimidin-5-ylamino)-6-(R)-tetrahydro-furan-3-yl-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide,3-(Pyrimidin-5-ylamino)-6-(S)-tetrahydro-furan-3-yl-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid{1-methyl-5-[(S)-(tetrahydro-furan-3-yl)carbamoyl]-1H-pyrazol-4-yl}-amide- , 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {1-methyl-5-[(R)-(tetrahydro-furan-3-yl)carbamoyl]-1H-pyrazol-4-yl}-amide- ,6-Morpholin-4-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [1-methyl-5-(1-methyl-azetidin-3-ylcarbamoyl)-1H-pyrazol-4-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-(isoxazolidine-2-carbonyl)-1-methyl-1H-pyrazol-4-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[5-(2-hydroxy-cyclopentylcarbamoyl)-1-methyl-1H-pyrazol-4-yl]-amide, and 6-(1-Hydroxy-1-methyl-ethyl)-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxyli- c acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, or a pharmaceutically acceptable salt thereof.

33. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein ##STR00429## is selected from the group consisting of: ##STR00430## wherein R.sup.12 is hydrogen or halogen; R.sup.13 is hydrogen, lower alkyl,lower-alkoxy-lower-alkyl, cycloalkyl or tetrahydrofuranyl; R.sup.14 is hydrogen or lower alkyl; R.sup.15 is hydrogen or halogen; R.sup.16 is hydrogen, halogen or diethylaminocarbonyl; R.sup.17 is hydrogen, halogen, lower alkyl, lower alkoxy, lowerhaloalkyl, cyano, 2-hydroxy-ethoxy, 2-methoxy-ethoxy, 2-hydroxy-2-methyl-propoxy, 2-(hydroxycarbonyl)ethyl, 2-ethoxycarbonyl-ethyl, methylcarbamoylmethoxy or acetylamino; and R.sup.18 is hydrogen, halogen, lower alkyl or lower alkoxy.

34. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.1 is lower alkyl or cycloalkyl.

35. The compound or a pharmaceutically acceptable salt thereof of claim 14, wherein R.sup.1 is isopropyl, isobutyl, tert-butyl or cyclopropyl.

36. The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, cycloalkyl or heterocyclyl, whereinsaid lower alkyl is optionally substituted by heterocyclyl, and wherein said heterocyclyl is optionally substituted by lower alkyl or R.sup.5 and R.sup.6, together with the nitrogen atom to which they are attached, form an azetidine, pyrrolidine,piperidine, piperazine or 2-oxa-6-aza-spiro[3.3]heptane ring, wherein each of said azetidine, pyrrolidine, piperazine or 2-oxa-6-aza-spiro[3.3]heptane ring is optionally substituted by 1 or 2 substituents independently selected from the group consistingof hydroxyl, halogen, lower alkyl, lower hydroxyalkyl, lower alkoxy, oxo and amino, and wherein said amino is substituted by 2 lower alkyl.

37. The compound or a pharmaceutically acceptable salt thereof of claim 16, wherein R.sup.5 and R.sup.6 are independently hydrogen, methyl, tetrahydrofuran-2-yl-methyl, ethyl, 2-hydroxy-1-methyl-ethyl, 2-hydroxy-1,1-dimethyl-ethyl,2-methoxyethyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-ethyl, 2-isopropoxy-ethyl, 2,2,2,-trifluoro-ethyl, isopropyl, 2,3-dihydroxy-propyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 2-methoxy-2-methyl-propyl, 3-methoxy-2,2-dimethyl-propyl, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuran-3-yl, oxetan-3-yl, 3-methyl-oxetan-3-yl or tetrahydro-pyran-4-yl, or R.sup.5 and R.sup.6, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl orspiro-heterocyclyl ring selected from the group consisting of azetidin-1-yl, 3-hydroxy-azetidin-1-yl, 3,3-difluoro-azetidin-1-yl, pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-methoxy-pyrrolidin-1-yl,2-hydroxymethyl-pyrrolidin-1-yl, 3-dimethylamino-pyrrolidin-1-yl, 2,5-dimethyl-pyrrolidin-1-yl, 2,2-dimethyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, piperidin-1-yl, 2-methyl-piperidin-1-yl, 3-oxo-piperazin-1-yl,3-methyl-morpholin-4-yl and 2-oxa-6-aza-spiro[3.3]heptan-6-yl.

38. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [4-(pyrrolidine-1-carbonyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylicacid (4-dimethylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (4-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (2-methylcarbamoyl-phenyl)-amide,6-Cyclopropyl-N-[4-(3-dimethylamino-pyrrolidine-1-carbonyl)-pyridin-3-yl]- -3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(2-methyl-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-(pyr- imidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[4-(3,3-difluoro-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-- (pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-(4-cyclopropylcarbamoyl-pyridin-3-yl)-3-(pyrimidin-5-ylam- ino)-pyridine-2-carboximidic acid,N-(4-Cyclobutylcarbamoyl-pyridin-3-yl)-6-cyclopropyl-3-(pyrimidin-5-ylami- no)-pyridine-2-carboximidic acid, and 6-Cyclopropyl-N-[4-(2,5-dimethyl-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-- (pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, or apharmaceutically acceptable salt thereof.

39. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-N-[4-(5-hydroxy-3,6-dihydro-2H-pyrazine-1-carbonyl)-pyridin- -3-yl]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,N-(4-Cyclopentylcarbamoyl-pyridin-3-yl)-6-cyclopropyl-3-(pyrimidin-5-ylam- ino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(3-methoxy-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-(py- rimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[4-(3,3-dimethyl-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-- (pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(2-hydroxy-1-methyl-ethylcarbamoyl)-pyridin-3-yl]-3-(p- yrimidin-5-ylamino)-pyridine-2-carboximidic acid,N-[4-(Azetidine-1-carbonyl)-pyridin-3-yl]-6-cyclopropyl-3-(pyrimidin-5-yl- amino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(2-hydroxy-ethylcarbamoyl)-pyridin-3-yl]-3-(pyrimidin-- 5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[4-(2,3-dihydroxy-propylcarbamoyl)-pyridin-3-yl]-3-(pyrim- idin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-3-(- pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, and6-Cyclopropyl-N-{4-[(3-hydroxy-propyl)-methyl-carbamoyl]-pyridin-3-yl}-3-- (pyrimidin-5-ylamino)-pyridine-2-carboximidic acid or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-N-[4-(2-methoxy-1-methyl-ethylcarbamoyl)-pyridin-3-yl]-3-(p- yrimidin-5-ylamino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-{4-[(2-hydroxy-ethyl)-methyl-carbamoyl]-pyridin-3-yl}-3-(- pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, N-(4-Cyclohexylcarbamoyl-pyridin-3-yl)-6-cyclopropyl-3-(pyrimidin-5-ylami- no)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[4-(3,3-difluoro-azetidine-1-carbonyl)-pyridin-3-yl]-3-(p- yrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-pyridin-3-yl]- -3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,7-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carbonyl]-amino}-2-p- henyl-imidazo[1,2-a]pyridine-6-carboxylic acid methylamide, 6-Cyclopropyl-N-[4-(3-hydroxy-azetidine-1-carbonyl)-pyridin-3-yl]-3-(pyri- midin-5-ylamino)-pyridine-2-carboximidicacid, 6-Cyclopropyl-N-[4-(2,2-dimethyl-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-- (pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-{4-[(2,3-dihydroxy-propyl)-methyl-carbamoyl]-pyridin-3-yl-}-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, and 6-Cyclopropyl-N-[4-(3-hydroxy-pyrrolidine-1-carbonyl)-pyridin-3-yl]-3-(py- rimidin-5-ylamino)-pyridine-2-carboximidic acid or a pharmaceutically acceptable salt thereof.

41. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-N-[4-(2-oxa-6-aza-spiro[3.3]heptane-6-carbonyl)-pyridin-3-y- l]-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid,2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid [4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, 2-tert-Butyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid [4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide,2-(2-tert-butyl-5-(pyrimidin-5-ylamino)pyrimidine-4-carboxamido)-N4,N4-di- ethyl-N1-methylterephthalamide, 5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-pyr- imidine-4-carboxylic acid (2-hydroxy-2-methyl-propyl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-isopropoxy-ethylcarbamoyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(tetrahydro-furan-3-ylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {4-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pyridin-3-yl}-amide,and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide or a pharmaceutically acceptable salt thereof.

42. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(oxetan-3-ylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[4,5-difluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-methoxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid [4-(3-methoxy-2,2-dimethyl-propylcarbamoyl)-pyridin-3-yl]-amide, 6-cyclopropyl-N-(2-((2-methoxyethyl)(methyl)carbamoyl)pyridin-3-yl)-3-(py- rimidin-5-ylamino)pyrazine-2-carboxamide,5-(6-cyclopropyl-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamido)-N-(2-meth- oxyethyl)-N-methylpyrimidine-4-carboxamide, 6-cyclopropyl-N-(3-(2-hydroxy-2-methylpropylcarbamoyl)pyridin-4-yl)-3-(py- rimidin-5-ylamino)pyrazine-2-carboxamide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(3-methyl-oxetan-3-ylcarbamoyl)-pyridin-3-yl]-amide, 5-(6-cyclopropyl-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamido)-N-(2-hydr- oxy-2-methylpropyl)-N-methylpyrimidine-4-carboxamide, and6-cyclopropyl-N-(2-((2-hydroxy-2-methylpropyl)(methyl)carbamoyl)pyridin-3- -yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof.

43. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (4-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[4-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(2-dimethylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (6-cyclopropyl-2-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[6-cyclopropyl-2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide- , 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-methylcarbamoyl-6-(tetrahydro-furan-2-yl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-6-(tetrahydro-furan-2-yl)-pyridin- -3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(6-ethyl-2-methylcarbamoyl-pyridin-3-yl)-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [6-ethyl-2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide or a pharmaceutically acceptable salt thereof.

44. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (6-methyl-2-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-6-methyl-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (3-methoxy-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(azetidine-1-carbonyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(piperidine-1-carbonyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(3-chloro-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(pyrrolidine-1-carbonyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(ethyl-methyl-carbamoyl)-pyridin-3-yl]-amide, 5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-pyr- imidine-4-carboxylic acid ethyl-methyl-amide, and 5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-pyr-imidine-4-carboxylic acid dimethylamide, or a pharmaceutically acceptable salt thereof.

45. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-3-methoxy-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(2-hydroxy-2-methyl-propylcarbamoyl)-4-isopropyl-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (4-isopropyl-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(6-methoxymethyl-2-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-6-methoxymethyl-pyridin-3-yl]-ami- de,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(azetidine-1-carbonyl)-pyrimidin-5-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(piperidine-1-carbonyl)-pyrimidin-5-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-4-(2-methoxy-ethoxy)-phenyl]-amid- e, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[4-(2-methoxy-ethoxy)-2-methylcarbamoyl-phenyl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-hydroxy-ethoxy)-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amid- e, or a pharmaceutically acceptable salt thereof.

46. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-hydroxy-ethoxy)-2-methylcarbamoyl-phenyl]-amide,5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-pyr- imidine-4-carboxylic acid methylamide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(pyrrolidine-1-carbonyl)-pyrimidin-5-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-ethylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-isopropylcarbamoyl-pyridin-3-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (3-methyl-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (4-methoxy-2-methylcarbamoyl-phenyl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {2-[methyl-(tetrahydro-pyran-4-yl)-carbamoyl]-pyridin-3-yl}-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid{2-[methyl-(2,2,2-trifluoro-ethyl)-carbamoyl]-pyridin-3-yl}-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(cyclopropyl-methyl-carbamoyl)-pyridin-3-yl]-amide, or a pharmaceutically acceptable salt thereof.

47. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-methyl-pyrrolidine-1-carbonyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-methyl-piperidine-1-carbonyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(3-methyl-morpholine-4-carbonyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (6-chloro-4-methylcarbamoyl-pyridin-3-yl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [6-chloro-4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (4-cyano-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-cyano-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (3,4-dimethyl-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (6-cyclopropyl-2-dimethylcarbamoyl-pyridin-3-yl)-amide, and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-6-methyl-pyridin-3-yl)-amide, or a pharmaceutically acceptable salt thereof.

48. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {2-[(2-hydroxy-ethyl)-methyl-carbamoyl]-pyridin-3-yl}-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {2-[ethyl-(2-hydroxy-ethyl)-carbamoyl]-pyridin-3-yl}-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-ethylcarbamoyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(azetidine-1-carbonyl)-6-cyclopropyl-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (4-acetylamino-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(3-methyl-oxetan-3-ylcarbamoyl)-pyridin-3-yl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid {2-[methyl-(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pyridin-3-yl}-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(oxetan-3-ylcarbamoyl)-pyridin-3-yl]-amide, and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(azetidine-1-carbonyl)-6-methyl-pyridin-3-yl]-amide, or a pharmaceutically acceptable salt thereof.

49. The compound of claim 1, selected from the group consisting of: 5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-2-m- ethyl-pyrimidine-4-carboxylic acid (2-hydroxy-2-methyl-propyl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-4,5-difluoro-phenyl)-amide, 5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-2-m- ethyl-pyrimidine-4-carboxylic acid methylamide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (4,5-difluoro-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-fluoro-6-methylcarbamoyl-phenyl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(azetidine-1-carbonyl)-4,5-difluoro-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (5-fluoro-2-methylcarbamoyl-phenyl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-fluoro-6-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-5-fluoro-phenyl)-amide, and6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-4-trifluoromethyl-phenyl]-amide, or a pharmaceutically acceptable salt thereof.

50. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-methylcarbamoyl-4-trifluoromethyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylicacid (2-dimethylcarbamoyl-4-fluoro-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (3,5-difluoro-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(2-dimethylcarbamoyl-3,5-difluoro-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [5-fluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(azetidine-1-carbonyl)-5-fluoro-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-6-fluoro-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(azetidine-1-carbonyl)-4-fluoro-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-fluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(3-fluoro-2-methylcarbamoyl-phenyl)-amide, or a pharmaceutically acceptable salt thereof.

51. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-3-fluoro-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(azetidine-1-carbonyl)-3-fluoro-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [3-fluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(4-fluoro-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-dimethylcarbamoyl-3,4-difluoro-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid(3,4-difluoro-2-methylcarbamoyl-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [3,4-difluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(azetidine-1-carbonyl)-3,4-difluoro-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [6-(azetidine-1-carbonyl)-2,3-difluoro-phenyl]-amide, and 3-(4-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}--3-methylcarbamoyl-phenyl)-propionic acid ethyl ester, or a pharmaceutically acceptable salt thereof.

52. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2-methylcarbamoyl-4-methylcarbamoylmethoxy-phenyl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(azetidine-1-carbonyl)-3,5-difluoro-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [3,5-difluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (6-dimethylcarbamoyl-2,3-difluoro-phenyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2,3-difluoro-6-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2,3-difluoro-6-methylcarbamoyl-phenyl)-amide, 3-(4-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-- 3-methylcarbamoyl-phenyl)-propionic acid,2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, 2-tert-Butyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide,2-Isobutyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[4-(2-hydroxy-2-methyl-propoxy)-2-methylcarbamoyl-phenyl]-amide, or a pharmaceutically acceptable salt thereof.

53. The compound of claim 1, selected from the group consisting of: 6-Cyclopropyl-N-(4-cyclopropylcarbamoyl-pyridin-3-yl)-3-(pyrimidin-5-ylam- ino)-pyridine-2-carboximidic acid,6-Cyclopropyl-N-[4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-3-(- pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-N-[4-(2-methoxy-1-methyl-ethylcarbamoyl)-pyridin-3-yl]-3-(p- yrimidin-5-ylamino)-pyridine-2-carboximidic acid,5-{[6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-pyr- imidine-4-carboxylic acid (2-hydroxy-2-methyl-propyl)-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid[4,5-difluoro-2-(2-hydroxy-2-methyl-propylcarbamoyl)-phenyl]-amide, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [4-(2-methoxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide,6-cyclopropyl-N-(2-((2-hydroxy-2-methylpropyl)(methyl)carbamoyl)pyridin-3- -yl)-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide, and 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (6-cyclopropyl-2-methylcarbamoyl-pyridin-3-yl)-amide,6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-6-methyl-pyridin-3-yl]-amide, 2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid[2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, and 2-tert-Butyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid [2-(2-hydroxy-2-methyl-propylcarbamoyl)-pyridin-3-yl]-amide, or a pharmaceutically acceptable salt thereof.

54. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I ##STR00431## wherein A.sup.1 is selected from the group consisting of CH and N; A.sup.2 is selected from the group consisting ofCR.sup.19 and N, provided that A.sup.1 and A.sup.2 are not N simultaneously; ##STR00432## is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 to 3 substituents independently selected from the group consisting oflower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, --C(O)--N(R.sup.8).sub.2, --N(R.sup.8)--C(O)-lower alkyl, cyano, halogen, R.sup.9 and amino, and wherein said lower alkyl is optionallysubstituted by oxo, --C(O)OH, lower alkoxy-C(O)-- or R.sup.7, and wherein said lower alkoxy is optionally substituted by hydroxyl, lower alkoxy or --C(O)--N(R.sup.8).sub.2, and wherein said amino is optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl and lower alkyl-C(O)--; R.sup.1 is lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, loweralkyl-C(O)--, --O-lower haloalkyl, cyano, halogen, R.sup.7 or amino, wherein said lower alkyl is optionally substituted by R.sup.7, and wherein said amino is optionally substituted by 1 or 2 substituents independently selected from the group consistingof lower alkyl and lower-alkoxy-lower-alkyl; R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl; R.sup.4 is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 to 3 substituents independently selectedfrom the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano and amino, and wherein said amino is optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl; R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl, lower alkoxy, lower haloalkyl, lower cyanoalkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl,cycloalkyl or heterocyclyl, wherein said lower alkyl is optionally substituted by oxo, R.sup.7 or --N(R.sup.8).sub.2, and wherein said lower haloalkyl is optionally substituted by hydroxyl, and wherein said cycloalkyl and said heterocyclyl are optionallysubstituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, acetyl, cyano, --C(O)-lower alkoxy and --N(R.sup.8).sub.2,or R.sup.5 and R.sup.6, together with the nitrogen atom to which they are attached, form a heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl and said spiro-heterocyclyl are optionally substituted by 1 to 3 substituents independently selectedfrom the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano, oxo and amino, and wherein said amino is optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl and lower-alkoxy-lower-alkyl; R.sup.7 is cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; R.sup.8 is independently selected from the group consisting of hydrogen, lower alkyl, lower hydroxyalkyl andlower-alkoxy-lower-alkyl; R.sup.9 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, said heterocyclyl, said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the groupconsisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; and R.sup.19 is hydrogen or tetrahydrofuran-2-yl; or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

55. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) ##STR00433## wherein A.sup.1 and A.sup.2 are independently selected from the group consisting of CH and N, provided that A.sup.1 andA.sup.2 are not N simultaneously; ##STR00434## is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl optionally substituted by oxoor R.sup.7, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, --C(O)--N(R.sup.8).sub.2, --N(R.sup.8)--C(O)-lower alkyl, cyano, halogen, R.sup.9 and amino optionally substituted by 1 or 2 substituentsindependently selected from the group consisting of lower alkyl, lower hydroxyalkyl and lower-alkoxy-lower-alkyl; R.sup.1 is lower alkyl optionally substituted by R.sup.7, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl,lower alkyl-C(O)--, cyano, halogen, R.sup.7 or amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl; R.sup.2 and R.sup.3 are independently hydrogen or loweralkyl; R.sup.4 is heteroaryl optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, loweralkyl-C(O)--, cyano and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower-alkoxy-lower-alkyl; R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl optionally substitutedby oxo or R.sup.7, lower haloalkyl, lower cyanoalkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 to 3 substituents independently selected fromthe group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, acetyl, cyano and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting oflower alkyl and lower-alkoxy-lower-alkyl, or R.sup.5 and R.sup.6, together with the nitrogen atom to which they are attached, form a heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl and said spiro-heterocyclyl are optionally substituted by 1to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, lower-alkoxy-lower-alkyl, lower alkyl-C(O)--, cyano, oxo and amino optionally substituted by 1 or 2substituents independently selected from the group consisting of lower alkyl, lower hydroxyalkyl and lower-alkoxy-lower-alkyl; R.sup.7 is cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 or 2substituents independently selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; R.sup.8 is independently selected from the group consisting of hydrogen, lower alkyl, lowerhydroxyalkyl and lower-alkoxy-lower-alkyl; and R.sup.9 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, said heterocyclyl, said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selectedfrom the group consisting of lower alkyl, lower hydroxyalkyl, lower-alkoxy-lower-alkyl, halogen and lower haloalkyl; or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Description:
 
 
  Recently Added Patents
Display systems with touch screens
Three-term predictive adder and/or subtracter
Azole derivatives, methods for producing the same, intermediate thereof, agro-horticultural agents
Preserving privacy of digital communication information
Digital broadcast receiver and method for processing caption thereof
Implantable neuro-stimulation electrode with fluid reservoir
LED lamp including heat dissipator
  Randomly Featured Patents
Process and apparatus for controlled and gentle heating or cooling of viscous solutions or melts of thermoplastics
Scanning microscope
Optical pickup driver having piezoelectric elements of different voltages at start and steady state
Cross-layer routing method in wireless sensor network
Method and apparatus for controlling caster heat removal by varying casting speed
Zoom compact camera
Unitary spray nozzle
Attention mechanism for immediately displaying/logging system checkpoints
Vehicular modular design multiple application rectifier assembly having outer lead integument
Vaned rotor for rotary mechanisms with bearings in vane slots